Efficacy and Safety between Insulin Glargine Products (LY2963016 and Lantus®) in Patients with T2DM: The ELEMENT 5 Study

被引：0
|
作者：
Pollom, Robyn K.
Lacaya, Lyndon B.
Ilag, Liza L.
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
963-P
引用
收藏
页码：A249 / A249
页数：1
相关论文
共 50 条
  • [21] Evaluation of immunogenicity of LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Huster, W. J.
    Costigan, T. M.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    Konrad, R. J.
    DIABETOLOGIA, 2014, 57 : S397 - S398
  • [22] Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2
    Perez-Nieves, Magaly
    Pollom, Robyn K.
    Duan, Ran
    Kabul, Samaneh
    DeLozier, Amy M.
    Kaushik, Puneet
    Lllag, Liza
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2018, 7 (02): : 56 - 62
  • [23] Comparison of duration of action of 2 insulin glargine products, LY2963016 and insulin glargine, in subjects with type 1 diabetes mellitus
    Linnebjerg, H.
    Heise, T.
    Zhang, X.
    Seger, M. E.
    Coutant, D.
    Chua, L.
    Lam, E.
    DIABETOLOGIA, 2014, 57 : S382 - S382
  • [24] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Xiang Yan
    Chen Feng
    Ying Lou
    Zhiguang Zhou
    Diabetes Therapy, 2022, 13 : 1161 - 1174
  • [25] Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (Lantus®): a Post Hoc Analysis of a Randomized, Open-Label, Phase 3 Trial
    Yan, Xiang
    Feng, Chen
    Lou, Ying
    Zhou, Zhiguang
    DIABETES THERAPY, 2022, 13 (06) : 1161 - 1174
  • [26] Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
    Ilag, Liza L.
    Costigan, Timothy M.
    Deeg, Mark A.
    Pollom, Robyn K.
    Chang, Curtis L.
    Konrad, Robert J.
    Prince, Melvin J.
    DIABETES THERAPY, 2017, 8 (03) : 545 - 554
  • [27] Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine
    Liza L. Ilag
    Timothy M. Costigan
    Mark A. Deeg
    Robyn K. Pollom
    Curtis L. Chang
    Robert J. Konrad
    Melvin J. Prince
    Diabetes Therapy, 2017, 8 : 545 - 554
  • [28] Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed-Ratio Combination vs. Insulin Glargine in Japanese Patients with T2DM
    Kaneto, Hideaki
    Takami, Akane
    Spranger, Robert
    Amano, Atsushi
    Watanabe, Daisuke
    Niemoeller, Elisabeth
    DIABETES, 2019, 68
  • [29] Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
    Hiroshi Nishiyama
    Tomotaka Shingaki
    Yumi Suzuki
    Liza L. Ilag
    Diabetes Therapy, 2018, 9 : 1469 - 1476
  • [30] Switching from reference glargine (Lantus) to biosimilar glargine (Basalog) in T2DM patients, uncontrolled on OAD's
    Praveen, R.
    Saboo, B.
    Gadve, S.
    Chopra, V.
    Reddy, S.
    Ramanathan, B.
    Kumar, S.
    Bhograj, A.
    Kapur, R.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 209
12345